Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-240 Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors and AML
NCT04372706Phase 2Terminated
- Sponsor
- Rubius Therapeutics
- Start
- May 2020
- Primary completion
- Nov 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of RTX-212 in solid tumor, acute myeloid leukemia (AML), sponsored by Rubius Therapeutics. Started May 2020; status: terminated.
02
Drugs
RTX-212
03
Conditions
solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04372706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372706.